Immunoglobulin vs placebo
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes onlyRR 1.08 [0.65, 1.79]4 studies · 238 participantsLow